Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 9, 2026, at the OptimizeRx Corporation (the "Company") 2026 Annual Meeting of Shareholders ("Annual Meeting"), shareholders approved an amendment (the "Amendment No. 2") to the OptimizeRx Corporation 2021 Equity Incentive Plan (the "Equity Plan") to increase the number of shares of common stock ("Common Stock") available for awards under the Equity Plan by 1,000,000 shares to 5,450,000 shares. A summary of the material terms of the 2021 Plan is incorporated herein by reference from pages 46-54 of the Company's proxy statement for the Annual Meeting, as filed with the SEC on April 30, 2026 (the "Proxy Statement"). The Amendment No. 2 is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 5.07 Submission of Matters to a Vote of Security Holders.

During the Annual Meeting, on June 9, 2026, shareholders were asked to consider and vote upon five proposals: (1) to elect seven directors, each to serve for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal; (2) to approve, on an advisory basis, the compensation of the Company's named executive officers; (3) to approve an amendment to the Equity Plan to increase the aggregate number of shares of Common Stock available for awards under the Equity Plan by 1,000,000 shares; (4) to approve an amendment to the Equity Plan to adopt an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for issuance under the Equity Plan; and (5) to ratify Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

On the record date of April 10, 2026, there were 18,765,075 shares of Common Stock issued and outstanding and entitled to vote at the Annual Meeting. For each proposal, the results of the shareholder voting were as follows: